The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Lumasiran (Brand name: Oxlumo™)
- Manufactured by
FDA-approved indication: Oxlumo™ is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate levels in pediatric and adult patients
National Library of Medicine Drug Information Portal